OnCo
ideasIdea

A platform trial of very-low-cost metronomic chemotherapy in LMIC common cancers

Frequent tiny doses of cheap old chemotherapy pills have shown surprising benefit in some cancers. A single large trial network in India and Africa could find out where this works and where it does not.

Metronomic regimens (low-dose oral methotrexate, cyclophosphamide, celecoxib) cost a few dollars a month and need no infusion. Tata Memorial trials showed a survival benefit for metronomic maintenance in head and neck cancer, but evidence in other tumours is thin and mostly single-centre. A multi-country platform trial with a shared control arm, adding and dropping regimens and tumour types, would generate definitive answers and could be run largely by nurses.

Hypothesis
In at least two of five common LMIC tumour types, a metronomic regimen will improve overall survival over best supportive care or standard palliative chemotherapy at less than 5% of the drug cost.
Rationale
Head-and-neck results and the biology of anti-angiogenic and immunomodulatory low-dose schedules give a plausible mechanism; the drugs are on every essential medicines list.
What would test it
Run a phase 3 platform across the National Cancer Grid and African partner sites with overall survival and quality of life as endpoints, with pre-specified futility stopping per arm.
Maturity
early clinical
Who has to act
research
Cost to try
Medium ($1M to $50M)
Years to first evidence
5
Bottlenecks it attacks

Connected

9top

Pages like this

not linked directly; found by shared links